News
INCR
2.707
+4.13%
0.107
InterCure: Bargain Israel Cannabis Play
InterCure Ltd. Has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel. The cannabis market in Israel is still limited to medical use, but the company is expected to grow the market in 2024. InterCure stock has rallied sharply off the post October 7 lows. The company is cheap at only about 1x sales, with growth catalysts for growth in 2024 and beyond.
Seeking Alpha · 2d ago
Weekly Report: what happened at INCR last week (0415-0419)?
Weekly Report · 2d ago
WIRE, CUTR and USEG are among premarket gainers
On the Move WIRE, CUTR and USEG are among premarket gainers. Longeveron (LGVN) and Hub Cyber Security (HUBC) are among the day's top Gainers. Korea Electric Power (KEP) is among the losers.
Seeking Alpha · 04/15 12:41
Weekly Report: what happened at INCR last week (0408-0412)?
Weekly Report · 04/15 12:25
Weekly Report: what happened at INCR last week (0401-0405)?
Weekly Report · 04/08 12:32
This Israeli Cannabis Operator Anticipates $95.4M In Revenue Despite Gaza Conflict
InterCure Ltd. Announced its preliminary results for the full year of 2023. InterCure expects sequential double digit quarterly growth during 2024. The company's shares were trading 0.74% lower at $2.69 on Monday. The Israeli cannabis company is doing business as Canndoc.
Benzinga · 04/01 18:13
Intercure Ltd. Submits SEC Compliance Report
TipRanks · 04/01 13:40
InterCure sees annual revenue of NIS 351 million
InterCure Ltd. Sees annual revenue of NIS 351 million. Shares in the company was up 5.5% in early trade. The company was affected by damages caused by the war between Hamas and Israel. InterCure expects its 2023 core profit to be over NIS 50 million.
Seeking Alpha · 04/01 13:35
INTERCURE LTD: EXPECTS TO RESUME SEQUENTIAL QUARTERLY GROWTH DURING 2024
Reuters · 04/01 13:09
Weekly Report: what happened at INCR last week (0325-0329)?
Weekly Report · 04/01 12:27
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
InterCure Ltd. Announced preliminary results for the full year of 2023. Annual revenue for 2023 is estimated at NIS 351 million. The Company expects to resume sequential quarterly growth during 2024. InterCure is the leading, profitable, and fastest growing cannabis company outside of North America.
Barchart · 04/01 08:09
Weekly Report: what happened at INCR last week (0318-0322)?
Weekly Report · 03/25 12:31
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
InterCure Ltd. Is the leading medical cannabis company outside of North America. The Federal Republic of Germany has passed the Cannabis Act. The reform is expected to take effect on April 1, 2024. InterCure expects to launch a series of products in Germany in the coming months.
Barchart · 03/22 10:58
Weekly Report: what happened at INCR last week (0311-0315)?
Weekly Report · 03/18 12:29
Weekly Report: what happened at INCR last week (0304-0308)?
Weekly Report · 03/11 12:23
Weekly Report: what happened at INCR last week (0226-0301)?
Weekly Report · 03/04 12:28
Weekly Report: what happened at INCR last week (0219-0223)?
Weekly Report · 02/26 12:49
Weekly Report: what happened at INCR last week (0212-0216)?
Weekly Report · 02/19 12:51
InterCure provides update regarding its Nir Oz facility
InterCure provides update regarding its Nir Oz facility. There is limited access to the Southern Israel Site. INCR has begun the process of restoring the facility in Kibbutz Nir Oz and is advancing its plans to restore the site. InCR is a subsidiary of Israel-based pharmaceutical company.
Seeking Alpha · 02/13 21:53
InterCure Provides an Update Regarding Nir Oz Facility
InterCure Ltd. Is the leading medical cannabis company in Israel and outside of North America. The Company is providing an update on the status of its facility in Kibbutz Nir Oz, Israel. The company is the largest producer of medical cannabis in the country.
Barchart · 02/13 15:46
More
Webull provides a variety of real-time INCR stock news. You can receive the latest news about Intercure Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About INCR
InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.